Literature DB >> 19379996

Tracking cardiac engraftment and distribution of implanted bone marrow cells: Comparing intra-aortic, intravenous, and intramyocardial delivery.

Shu-Hong Li1, Teresa Y Y Lai, Zhuo Sun, Mihan Han, Eduardo Moriyama, Brian Wilson, Shafie Fazel, Richard D Weisel, Terrence Yau, Joseph C Wu, Ren-Ke Li.   

Abstract

OBJECTIVES: Cell therapy improved cardiac function after a myocardial infarction in several preclinical studies; however, the functional benefits were limited in the initial clinical trials, perhaps because of inadequate cell engraftment. We used noninvasive molecular imaging to compare the distribution and myocardial retention of cells implanted by using clinical delivery routes.
METHODS: Bone marrow stromal cells isolated from male rats and transfected with a firefly luciferase reporter gene were injected by using 3 increasingly invasive techniques (ie, intravenous, intra-aortic, and intramyocardial) into female rats 3 or 28 days after coronary ligation. Whole-body bioluminescence imaging was performed 2, 24, and 48 hours later; implanted cells were quantified at 48 hours in explanted organs by means of bioluminescence and real-time polymerase chain reaction.
RESULTS: Variations in cell distribution among groups were profound, with nearly complete trapping of the injected cells in the lungs after intravenous delivery. Cell delivery into the aortic root (with the distal aorta occluded) produced minimal cell retention in the heart. Direct intramyocardial injection facilitated the best early targeting of the cells (P < .05 vs intravenous and intra-aortic injection). Rapid signal loss over 48 hours indicated very poor cell survival in all 3 groups, although implanted cell retention was greater in mature compared with acute infarcts.
CONCLUSIONS: This is the first study to correlate live cell imaging with quantitative genetic and histologic techniques. Noninvasive molecular imaging tracked delivered cells and will permit the evaluation of new and improved delivery platforms designed to increase cell homing, retention, and engraftment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19379996     DOI: 10.1016/j.jtcvs.2008.11.001

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  37 in total

1.  Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly luciferase.

Authors:  Sophie E Boddington; Tobias D Henning; Priyanka Jha; Christopher R Schlieve; Lydia Mandrussow; David DeNardo; Harold S Bernstein; Carissa Ritner; Daniel Golovko; Ying Lu; Shoujun Zhao; Heike E Daldrup-Link
Journal:  Cell Transplant       Date:  2010       Impact factor: 4.064

2.  Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium.

Authors:  Ann C Gaffey; Minna H Chen; Chantel M Venkataraman; Alen Trubelja; Christopher B Rodell; Patrick V Dinh; George Hung; John W MacArthur; Renganaden V Soopan; Jason A Burdick; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-17       Impact factor: 5.209

Review 3.  Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy.

Authors:  John W MacArthur; Amanda N Steele; Andrew B Goldstone; Jeffrey E Cohen; William Hiesinger; Y Joseph Woo
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

4.  Externally Applied Static Magnetic Field Enhances Cardiac Retention and Functional Benefit of Magnetically Iron-Labeled Adipose-Derived Stem Cells in Infarcted Hearts.

Authors:  Jian Wang; Bo Xiang; Jixian Deng; Hung-Yu Lin; Dayang Zheng; Darren H Freed; Rakesh C Arora; Ganghong Tian
Journal:  Stem Cells Transl Med       Date:  2016-07-08       Impact factor: 6.940

5.  Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function.

Authors:  Pavan Atluri; Jordan S Miller; Robert J Emery; George Hung; Alen Trubelja; Jeffrey E Cohen; Kelsey Lloyd; Jason Han; Ann C Gaffey; John W MacArthur; Christopher S Chen; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-28       Impact factor: 5.209

Review 6.  Vascular stem cells-potential for clinical application.

Authors:  Sadie C Slater; Michele Carrabba; Paolo Madeddu
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

7.  Increased oxygen consumption and OXPHOS potential in superhealer mesenchymal stem cells.

Authors:  Curtis C Hughey; Maria P Alfaro; Darrell D Belke; Jeffery N Rottman; Pampee P Young; David H Wasserman; Jane Shearer
Journal:  Cell Regen (Lond)       Date:  2012-06-28

8.  At a crossroad: cell therapy for cardiac repair.

Authors:  Marcus-André Deutsch; Anthony Sturzu; Sean M Wu
Journal:  Circ Res       Date:  2013-03-15       Impact factor: 17.367

Review 9.  Stem cell therapy: pieces of the puzzle.

Authors:  John A Schoenhard; Antonis K Hatzopoulos
Journal:  J Cardiovasc Transl Res       Date:  2009-11-19       Impact factor: 4.132

10.  Grafts enriched with subamnion-cord-lining mesenchymal stem cell angiogenic spheroids induce post-ischemic myocardial revascularization and preserve cardiac function in failing rat hearts.

Authors:  Eliana C Martinez; Duc-Thang Vu; Jing Wang; Shera Lilyanna; Lieng H Ling; Shu U Gan; Ai Li Tan; Thang T Phan; Chuen N Lee; Theo Kofidis
Journal:  Stem Cells Dev       Date:  2013-08-31       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.